Treatment with single-agent (CBDCA or anti-PD-1 antibodies) temporarily reduced tumor size at Day 48 (Supplemental Tables 7–9), but could not prolong the survival (Supplemental Tables 10–12). This evidence concerns the gene PDCD1 and neoplasm.